VIP Peptide (Vasoactive Intestinal Peptide): Benefits, Mechanism, Side Effects, and How to Buy Safely

How vasoactive intestinal peptide works across the gut, nervous system, and immune system, what the research does and does not show, and what to check before you buy VIP for research.

What Vasoactive Intestinal Peptide (VIP) Is

Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide, a short signaling protein your body makes and uses as both a nerve messenger (a neurotransmitter) and a hormone. It belongs to the secretin and glucagon family of peptides, which also includes gastric inhibitory polypeptide (GIP). It was first found in the gut, which is where the name comes from, but it turns up across many tissues. If you are new to this class of molecules, start with what peptides are.

Two very different things share the name VIP, and keeping them apart matters:

• Endogenous VIP: the peptide your own cells release. Its actions here are settled physiology.
• Synthetic VIP: a lab-made copy sold as a research chemical, or made by a licensed pharmacy for specialist use. This form is not approved by the US FDA for any wellness or treatment use, and human outcome data is thin. Most online supply is sold research-use only.

This guide covers both. The synthetic side is framed as investigational only.

Where VIP Comes From in the Body

Your body makes VIP mainly in nerve cells, not glands. The main sources:

• Enteric neurons, the nerve network in the wall of the gastrointestinal tract (the myenteric and submucosal plexuses)
• Parasympathetic nerve fibers that supply the gut, pancreas, lungs, and blood vessels
• Neurons in the brain, including the hypothalamus, where VIP helps run the body clock
• Endocrine cells in the gut lining (the mucous membrane) and the pancreas

VIP nerve fibers reach far beyond the gut, into organs like the kidney and thyroid. That wide spread is why biohackers describe VIP as a brain-gut-immune signal: one molecule touching digestion, sleep timing, and inflammation at once.

How VIP Works (Mechanism)

VIP is a ligand that acts as an agonist at two main receptors, VPAC1 and VPAC2, which are its high-affinity targets. A third receptor, PAC1, mostly answers to VIP's chemical cousin PACAP and binds VIP only weakly, so it plays a minor role in VIP pharmacology.

When VIP lands on VPAC1 or VPAC2, the receptor switches on an enzyme called adenylyl cyclase, which raises an internal messenger called cAMP. That single switch drives most of what VIP does:

• Relaxes smooth muscle in the gut (helping peristalsis, the wave that moves food along), the airways, and blood vessels
• Widens blood vessels (vasodilation), which can lower blood pressure
• Opens the airways (bronchodilation, meaning it relaxes the airway muscle)
• Triggers the gut and pancreas to release water and electrolytes (a secretagogue effect), while damping gastric acid in the stomach
• Dials down inflammation

VIP Benefits and Research-Interest Areas

Most of what follows is normal physiology or early research, much of it in mouse and other animal models. None of it is an approved treatment.

• Digestive: VIP relaxes gut muscle, supports the release of water and electrolytes, and helps regulate blood flow to the gut lining. Its interplay with the gut microbiota is an active area of study within gastroenterology.
• Immune: researchers study VIP as an anti-inflammatory signal that shifts the balance of CD4+ T cells, favors regulatory T cells, and lowers pro-inflammatory cytokines, which is why it appears in autoimmune disease research.
• Respiratory: because VIP relaxes airway muscle, its synthetic analog aviptadil has been tested in lung conditions, covered below.
• Cardiovascular: VIP is a potent vasodilator across the circulatory system, which is also the source of its main side effects.
• Nervous system: in the brain, VIP helps set circadian rhythm and is studied for neuroprotection, synaptic plasticity, and mental focus; in peripheral nerves, it is explored for nerve support after injury.
• Joints: in mouse models of rheumatoid arthritis and osteoarthritis, VIP has been studied for lowering inflammatory cytokines and promoting immune tolerance. This work is preclinical.
• Endocrine: VIP also acts as a hormone, prompting the pituitary gland to release prolactin.

VIP Side Effects and Who Should Be Cautious

VIP's risks come straight from its biology: it widens blood vessels and drops blood pressure. Reported effects, drawn mostly from trials and case reports of the synthetic forms, include:

• Flushing and a warm sensation
• Headache
• Dizziness or lightheadedness
• Short drops in blood pressure and palpitations
• Mild nausea, bloating, or loose stools
• With nasal use, congestion or minor nosebleeds in the nasal mucous membrane; with injection, injection-site reactions

Nasal and injectable forms differ. Injected or infused VIP reaches the bloodstream fast, so the blood-pressure and heart effects show up more sharply. Nasal use tends toward local effects plus milder vasodilatory symptoms.

Some people carry higher risk and should not experiment with VIP outside supervised research:

• Low baseline blood pressure
• Heart disease or uncontrolled arrhythmias
• Active gastrointestinal bleeding
• Pregnancy

VIP is potent and short-acting, and human outcome data is limited. Using it alone, without monitoring, is a real risk, not a cautious footnote.

How VIP Is Used in Research and the Clinic

VIP shows up in three separate contexts:

• Diagnosis: clinicians measure VIP in blood plasma when a VIPoma is suspected. A VIPoma is a rare VIP-secreting neuroendocrine neoplasm, usually in the pancreas, that drives heavy watery diarrhea, low potassium, and sometimes high blood calcium (hypercalcemia). It can appear as part of MEN1, an inherited syndrome that also involves pituitary and parathyroid tumors. This context measures VIP; it does not give it.
• The analog aviptadil: a synthetic VIP agonist that holds FDA Fast Track status but is not approved. It has been tested for pulmonary arterial hypertension and for COVID-19 respiratory failure, partly because lab studies showed VIP can blunt viral RNA replication. The large TESICO trial run by the US National Institutes of Health found aviptadil did not significantly improve outcomes versus placebo. Aviptadil clears largely through the kidney.
• Compounded VIP: some licensed compounding pharmacies make nasal or injectable VIP for specialist use, such as certain chronic-inflammation protocols. This stays experimental and prescription-only.

Across all three, routes include IV infusion, injection under the skin, and inhaled or nasal delivery, and any dosing belongs inside a clinical protocol, not a home cabinet. Understanding the FDA's stance on peptides is worth doing before sourcing anything.

How to Buy VIP Peptide Safely (Research Use)

For most online suppliers, VIP is sold research-use-only and labeled not for human use. Compounded VIP is a separate channel: prescription-only, through a licensed provider. Buying research VIP for self-experimentation is discouraged and may break local law.

If you are sourcing for legitimate research, hold vendors to hard quality markers:

• A certificate of analysis (COA) tied to the exact lot
• Independent third-party testing by HPLC and mass spectrometry, with purity at or above 99%
• A stable freeze-dried (lyophilized) product with cold-chain shipping
• Clear research-use labeling, plus batch and expiry details

Sourcing VIP for research? Quality is the whole game. Our Vendor Directory lists suppliers that publish per-lot certificates of analysis and independent purity testing, so you can vet a lab before you buy rather than after.

VIP (Vasoactive Intestinal Peptide) FAQ

References

1. Harmar AJ, et al. Pharmacology of receptors for VIP and PACAP: IUPHAR Review 1. Br J Pharmacol. https://pmc.ncbi.nlm.nih.gov/articles/PMC3415633/
2. Liao C, et al. Targeting VIP and PACAP receptor signaling: receptor affinity and tissue distribution. Int J Mol Sci. https://pmc.ncbi.nlm.nih.gov/articles/PMC9331257/
3. Moss RB, et al. PACAP/VIP biology, pharmacology, and cellular signaling. https://pmc.ncbi.nlm.nih.gov/articles/PMC7957349/
4. Brown SM, et al. Intravenous aviptadil and remdesivir for COVID-19 hypoxaemic respiratory failure (TESICO). Lancet Respir Med. 2023. https://pubmed.ncbi.nlm.nih.gov/37348524/
5. Zyesami (aviptadil): FDA approval status and regulatory history. Drugs.com. https://www.drugs.com/history/zyesami.html